These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 9231547)

  • 1. Comparison of clinical outcome of fixed-dose subcutaneous low molecular weight heparin (tinzaparin) with conventional heparin in unstable angina: a pilot study.
    Suvarna TT; Parikh JA; Keshav R; Pillai MG; Pahlajani DB; Gandhi MJ
    Indian Heart J; 1997; 49(2):159-62. PubMed ID: 9231547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative efficacy of once daily parnaparin and unfractionated heparin in unstable angina pectoris: PRIME CARE study.
    PRIME CARE Study Investigators Group
    Indian Heart J; 2005; 57(6):648-54. PubMed ID: 16521631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia.
    Gurfinkel EP; Manos EJ; Mejaíl RI; Cerdá MA; Duronto EA; García CN; Daroca AM; Mautner B
    J Am Coll Cardiol; 1995 Aug; 26(2):313-8. PubMed ID: 7608429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
    Cohen M; Demers C; Gurfinkel EP; Turpie AG; Fromell GJ; Goodman S; Langer A; Califf RM; Fox KA; Premmereur J; Bigonzi F
    N Engl J Med; 1997 Aug; 337(7):447-52. PubMed ID: 9250846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The role of low-molecular-weight heparin in unstable angina, acute myocardial infarction and post-elective percutaneous transluminal coronary angioplasty].
    Cláudio Correia LC; Neubauer C; Azevedo A; Ribeiro F; Braga J; Carlos Passos L; Teixeira M; Matos M; Aires V; Souza V
    Arq Bras Cardiol; 1995 Dec; 65(6):475-8. PubMed ID: 8731298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis.
    Oler A; Whooley MA; Oler J; Grady D
    JAMA; 1996 Sep; 276(10):811-5. PubMed ID: 8769591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes.
    Flather MD; Weitz JI; Yusuf S; Pogue J; Sussex B; Campeau J; Gill J; Schuld R; Joyner CD; Morris AL; Lai C; Théroux P; Marquis JF; Chan YK; Venkatesh G; Jessel A
    Eur Heart J; 2000 Sep; 21(17):1473-81. PubMed ID: 10952840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomised comparison of subcutaneous heparin, intravenous heparin, and aspirin in unstable angina. Studio Epoorine Sottocutanea nell'Angina Instobile (SESAIR) Refrattorie Group.
    Neri Serneri GG; Modesti PA; Gensini GF; Branzi A; Melandri G; Poggesi L; Rostagno C; Tamburini C; Carnovali M; Magnani B
    Lancet; 1995 May; 345(8959):1201-4. PubMed ID: 7739307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome).
    Eur Heart J; 1999 Nov; 20(21):1553-62. PubMed ID: 10529323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of a very low molecular weight heparin compared with standard heparin in patients with unstable angina: a pilot study.
    Mattioli AV; Castellani ET; Goedecke L; Sormani L; Sternieri S; Mattioli G
    Clin Cardiol; 1999 Mar; 22(3):213-7. PubMed ID: 10084064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparison of low-molecular-weight heparin and unfractionated heparin in the treatment of unstable angina].
    Godoy I; Herrera C; Zapata C; Kunstmann S; Abufhele A; Corbalán R
    Rev Med Chil; 1998 Mar; 126(3):259-64. PubMed ID: 9674294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A meta-analysis of controlled clinical trials comparing low-molecular weight heparins with unfractionated heparin in unstable angina.
    Malhotra S; Karan RS; Bhargava VK; Pandhi P; Grover A; Sharma YP; Kumar R
    Indian Heart J; 2001; 53(2):197-202. PubMed ID: 11428477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
    Horbach T; Wolf H; Michaelis HC; Wagner W; Hoffmann A; Schmidt A; Beck H
    Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-molecular-weight heparin versus unfractionated heparin for unstable coronary disease.
    Kearon C
    N Engl J Med; 1998 Jan; 338(2):129-30; author reply 131. PubMed ID: 9424582
    [No Abstract]   [Full Text] [Related]  

  • 15. Low-molecular-weight heparin vs. unfractionated heparin in percutaneous coronary intervention: a combined analysis.
    Borentain M; Montalescot G; Bouzamondo A; Choussat R; Hulot JS; Lechat P
    Catheter Cardiovasc Interv; 2005 Jun; 65(2):212-21. PubMed ID: 15900551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of a low molecular mass thrombin inhibitor, inogatran, and heparin on thrombin generation and fibrin turnover in patients with unstable coronary artery disease.
    Linder R; Oldgren J; Egberg N; Grip L; Larson G; Siegbahn A; Wallentin L
    Eur Heart J; 1999 Apr; 20(7):506-18. PubMed ID: 10365287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved in-hospital outcomes in acute coronary syndromes (unstable angina/non-ST segment elevation myocardial infarction) despite similar TIMI risk scores.
    Almeda FQ; Hendel RC; Nathan S; Meyer PM; Calvin JE; Klein LW
    J Invasive Cardiol; 2003 Sep; 15(9):502-6. PubMed ID: 12947210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activated partial thromboplastin time and clinical outcome after thrombin inhibition in unstable coronary artery disease.
    Oldgren J; Linder R; Grip L; Siegbahn A; Wallentin L
    Eur Heart J; 1999 Nov; 20(22):1657-66. PubMed ID: 10543929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis. Certoparin-Study Group.
    Kirchmaier CM; Wolf H; Schäfer H; Ehlers B; Breddin HK
    Int Angiol; 1998 Sep; 17(3):135-45. PubMed ID: 9821025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fixed-dose, body weight-independent subcutaneous low molecular weight heparin Certoparin compared with adjusted-dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis.
    Riess H; Koppenhagen K; Tolle A; Kemkes-Matthes B; Gräve M; Patek F; Drexler M; Siemens HJ; Harenberg J; Weidinger G; Brom J; Haas S;
    Thromb Haemost; 2003 Aug; 90(2):252-9. PubMed ID: 12888872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.